Immune modulation to treat Alzheimer’s disease
In addition to approved amyloid beta monoclonal therapies, targeting immune cells and immunologically relevant molecules may offer opportunities to treat Alzheimer’s disease as neuroinflammation plays a critical role in the pathogenesis of the disease.
The researchers in this review, provide an overview of immunomodulatory therapeutics in development, including their preclinical evidence and clinical trial results.
They also discuss various immune mechanisms involved in AD pathogenesis and ways to target them to modify disease progression.
They also summarize knowledge gained from previous trials of immune-based interventions, and provide a series of recommendations for the development of future immunomodulatory therapeutics to treat AD.
https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-025-00828-x
